The association between plasma matrix metalloproteinase-9 concentration and endoleak after endovascular aortic aneurysm repair: A meta-analysis

Atherosclerosis

Volumn 242, Issue 2, 2015, Pages 535-542

  Ng, Eugene ^a,b,c   Morris, Dylan R ^b   Golledge, Jonathan ^a,b,c  

^a TOWNSVILLE HOSPITAL   (Australia)

^b JAMES COOK UNIVERSITY   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Biomarkers; Circulating markers; Endoleak; Endovascular repair of aneurysm; EVAR; Plasma markers

Indexed keywords

GELATINASE A; GELATINASE B; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; MMP9 PROTEIN, HUMAN;

AORTA ANEURYSM; AORTIC ANEURYSM ENDOVASCULAR GRAFT; ARTICLE; DACRON IMPLANT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENDOLEAK; ENDOVASCULAR ANEURYSM REPAIR; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; META ANALYSIS; PRIORITY JOURNAL; QUALITY CONTROL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; ADVERSE EFFECTS; AORTIC ANEURYSM, ABDOMINAL; BLOOD; BLOOD VESSEL TRANSPLANTATION; ENDOVASCULAR SURGERY; FEMALE; MALE; POSTOPERATIVE COMPLICATION; RISK FACTOR; TREATMENT OUTCOME;

AORTIC ANEURYSM, ABDOMINAL; BLOOD VESSEL PROSTHESIS IMPLANTATION; ENDOLEAK; ENDOVASCULAR PROCEDURES; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84939824381     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.08.016     Document Type: Article

References (21)

1. Sampson U.K., Norman P.E., Fowkes F.G., Aboyans V., Song Yanna, Harrell F.E., Forouzanfar M.H., Naghavi M., Denenberg J.O., McDermott M.M., Criqui M.H., Mensah G.A., Ezzati M., Murray C. Global and regional burden of aortic dissection and aneurysms: mortality trends in 21 world regions, 1990 to 2010. Glob. Heart 2014 Mar, 9(1):171-180.e10.
2. Golledge J., Tsao P.S., Dalman R.L., Norman P.E. Circulating markers of abdominal aortic aneurysm presence and progression. Circulation 2008, 118:2382-2392.
3. Rao S.K., Reddy K.V., Cohen J.R. Role of serine proteases in aneurysm development. Ann. N. Y. Acad. Sci. 1996, 800:131-137.
4. McMillan W.D., Tamarina N.A., Cipollone M., Johnson D.A., Parker M.A., Pearce W.H. Size matters: the relationship between MMP-9 expression and aortic diameter. Circulation 1997, 96:2228-2232.
5. Moher D., Liberati A., Tetzlaff J., Altman D.G., Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 2009, 151:264-269.
6. Higgins J.P., Altman D.G., Gotzsche P.C., Juni P., Moher D., Oxman A.D., Savovic J., Schulz K.F., Weeks L., Sterne J.A. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011, 343:d5928. Cochrane Bias Methods G, Cochrane Statistical Methods G.
7. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 2010, 25:603-605.
8. Monaco M., Stassano P., Di Tommaso L., Iannelli G.J. Response of plasma matrix metalloproteinases and tissue inhibitor of metalloproteinases to stent-graft surgery for descending thoracic aortic aneurysms. Thorac. Cardiovasc. Surg. 2007 Oct, 134(4):925-931. PMID: 17903509.
9. Hellenthal F.A., Ten Bosch J.A., Pulinx B., Wodzig W.K., de Haan M.W., Prins M.H., Welten R.J., Teijink J.A., Schurink G.W. Plasma levels of matrix metalloproteinase-9: a possible diagnostic marker of successful endovascular aneurysm repair. Eur. J. Vasc. Endovasc. Surg. 2012 Feb, 43(2):171-172. Epub 2011 Dec 14. PMID: 22172237. 10.1016/j.ejvs.2011.10.014.
10. Sangiorgi G., D'Averio R., Mauriello A., Bondio M., Postillo M., Castelvecchio S., et al. Plasma levels of metalloproteinases-3 and -9 as markers of successful abdominal aortic aneurysm exclusion after endovascular graft treatment. Circulation 2001, 104(Suppl. I):I-288-I-295. PMID: 11568071.
11. Lorelli D.R., Jean-Claude J.M., Fox C.J., Clyne J., Cambria R.A., Seabrook G.R., Towne J.B. Response of plasma matrix metalloproteinase-9 to conventional abdominal aortic aneurysm repair or endovascular exclusion: implications for endoleak. J. Vasc. Surg. 2002 May, 35(5):916-922. PMID: 12021707.
12. Nakamura E., Akashi H., Hiromatsu S., Tanaka A., Onitsuka S., Aoyagi S. Azelnidipine decreases plasma matrix metalloproteinase-9 levels after endovascular abdominal aortic aneurysm repair. Kurume Med. J. 2009, 56(1-2):25-32.
13. Antoniou G.A., Georgiadis G.S., Antoniou S.A., Murray D., Smyth J.V., Serracino-Inglott F., Paraskevas K.I. Plasma matrix metalloproteinase 9 levels may predict endoleaks after endovascular aortic aneurysm repair. Angiology 2013 Jan, 64(1):49-56.
14. Taurino M., Visco V., Raffa S., Ricci B., Ruggiero M., Torrisi M.R., Fiorani P. Matrix metalloproteinase 9 activity in patients before and after endovascular or surgical repair of abdominal aortic aneurysms. Vascular 2004, 12:312-317.
15. Hackmann A.E., Rubin B.G., Sanchez L.A., Geraghty P.A., Thompson R.W., Curci J.A. A randomized, placebo-controlled trial of doxycycline after endoluminal aneurysm repair. J. Vasc. Surg. 2008, 48:519-526.
16. Shah A., Stavropoulos S.W. Imaging surveillance following endovascular aneurysm repair. Semin. Interv. Radiol. 2009, 26(1):10-16.
17. Peppelenbosch N., Buth J., Harris P.L., et al. Diameter of abdominal aortic aneurysm and outcome of endovascular aneurysm repair: does size matter? A report from EUROSTAR. J. Vasc. Surg. 2004, 39:288-297.
18. Zarins C.K., Crabtree T., Bloch D.A., et al. Endovascular aneurysm repair at 5 years: does aneurysm diameter predict outcome?. J. Vasc. Surg. 2006, 44:920-929. discussion 9-31.
19. Frego M., Lumachi F., Bianchera G., et al. Risk factors of endoleak following endovascular repair of abdominal aortic aneurysm. A multicentric retrospective study. In Vivo 2007, 21:1099-1102.
20. Evans J., Powell J.T., Schwalbe E., Loftus I.M., Thompson M.M. Simvastatin attenuates the activity of matrix metalloprotease-9 in aneurysmal aortic tissue. Eur. J. Vasc. Endovasc. Surg. 2007, 34(3):302-303.
21. Takigawa M., Yoshimuta T., Akutsu K., Takeshita S., Yokoyama N. Prevalence and predictors of coexistent silent atherosclerotic cardiovascular disease in patients with abdominal aortic aneurysm without previous symptomatic cardiovascular diseases. Angiology 2012, 63(5):380-385.